Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08AMQ
|
||||
| Former ID |
DIB005827
|
||||
| Drug Name |
SB-234551
|
||||
| Synonyms |
2-[2-[1-Butyl-4-[2-carboxy-3-(6-methoxy-1,3-benzodioxol-5-yl)-1(E)-propenyl]pyrazol-5-yl]-5-methoxyphenoxymethyl]benzoic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C34H34N2O9
|
||||
| InChI |
InChI=1S/C34H34N2O9/c1-4-5-12-36-32(27-11-10-25(41-2)16-29(27)43-19-21-8-6-7-9-26(21)34(39)40)24(18-35-36)14-23(33(37)38)13-22-15-30-31(45-20-44-30)17-28(22)42-3/h6-11,14-18H,4-5,12-13,19-20H2,1-3H3,(H,37,38)(H,39,40)/b23-14+
|
||||
| InChIKey |
MCHCGWZNXSZKJY-OEAKJJBVSA-N
|
||||
| CAS Number |
CAS 188257-75-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Endothelin-1 receptor | Target Info | Antagonist | [526119], [551871] | |
| NetPath Pathway | IL4 Signaling Pathway | ||||
| PANTHER Pathway | Endothelin signaling pathway | ||||
| Pathway Interaction Database | Endothelins | ||||
| EGFR-dependent Endothelin signaling events | |||||
| References | |||||
| Ref 538610 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1000). | ||||
| Ref 546574 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009010) | ||||
| Ref 526119 | Effects of the novel selective endothelin ET(A) receptor antagonist, SB 234551, on the cardiovascular responses to endotoxaemia in conscious rats. Br J Pharmacol. 2001 Aug;133(8):1371-7. | ||||
| Ref 551871 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.